Abstract 14509: Multicenter Randomized Controlled Trial Between Febuxostat and Allopurinol in Chronic Heart Failure Patients With Hyperuricemia

Background: Hyperuricemia is known as a marker of oxidative stress and associated with adverse prognosis in patients with chronic heart failure (CHF). Febuxostat, a novel non-purine selective xanthine oxidase inhibitor, is currently available for hyperuricemia and chronic goat. The purpose of this study was to compare the effects of febuxostat and allopurinol, a purine analog and conventional xanthine oxidase inhibitor, on cardiac function and prognosis in CHF patients with hyperuricemia. Methods and Results: We enrolled 272 stable CHF patients with hyperuricemia (serum uric acid level >7.0 mg/dl), and randomly assigned to febuxostat (n=127) or allopurinol (n=135) treatment groups. There was no difference in baseline clinical characteristics including age, gender, blood pressure, blood tests, and echocardiographic data between the two groups. All subjects were followed up after enrollment. Two years after enrollment, uric acid levels in both groups were significantly decreased (8.47 ± 1.24 to 5.54 ± 1.27 ...